Replimune Group (NASDAQ:REPL) Receives "Neutral" Rating from Wedbush

Key Points

• Wedbush reissued a "neutral" rating and slashed its price target to $2.00 (from $19.00), implying roughly a 58% downside from the current share price.
• Analyst consensus on Replimune is a "Reduce" with an average price target of $6.13; the breakdown is 2 Buys, 4 Holds and 4 Sells.
• Replimune is a clinical‑stage biotech trading around $4.77 with a market cap of about $394M, a 12‑month range of $2.68–$13.24, and negative earnings (Q reported EPS -$0.77; FY forecast -2.97).

Replimune Group (NASDAQ:REPL - Get Free Report)'s stock had its "neutral" rating reissued by equities research analysts at Wedbush in a research report issued on Monday,Benzinga reports. They currently have a $2.00 price target on the stock, down from their prior price target of $19.00. Wedbush's target price indicates a potential downside of 58.08% from the stock's current price.

Other equities research analysts have also recently issued reports about the company. Piper Sandler cut Replimune Group from an "overweight" rating to a "neutral" rating and set a $4.00 price target for the company. in a research note on Friday. Weiss Ratings reissued a "sell (d-)" rating on shares of Replimune Group in a report on Monday, December 29th. JPMorgan Chase & Co. reissued an "underweight" rating on shares of Replimune Group in a report on Monday. Finally, HC Wainwright reissued a "sell" rating on shares of Replimune Group in a report on Monday. Two investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and four have assigned a Sell rating to the stock. According to MarketBeat.com, Replimune Group has a consensus rating of "Reduce" and an average target price of $6.13.

Replimune Group Price Performance

NASDAQ REPL opened at $4.77 on Monday. The firm's fifty day simple moving average is $7.51 and its two-hundred day simple moving average is $7.95. The firm has a market capitalization of $393.94 million, a P/E ratio of -1.39 and a beta of 0.74. The company has a current ratio of 5.60, a quick ratio of 5.60 and a debt-to-equity ratio of 0.33. Replimune Group has a 12-month low of $2.68 and a 12-month high of $13.24.

Replimune Group (NASDAQ:REPL - Get Free Report) last posted its quarterly earnings data on Tuesday, February 3rd. The company reported ($0.77) earnings per share for the quarter, topping analysts' consensus estimates of ($0.85) by $0.08. Analysts forecast that Replimune Group will post -2.97 EPS for the current fiscal year.

Insider Activity at Replimune Group

In other news, insider Christopher Sarchi sold 6,500 shares of Replimune Group stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $8.01, for a total transaction of $52,065.00. Following the completion of the sale, the insider directly owned 151,588 shares in the company, valued at approximately $1,214,219.88. The trade was a 4.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 5.20% of the company's stock.

Institutional Investors Weigh In On Replimune Group

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Invesco Ltd. lifted its stake in shares of Replimune Group by 297.3% during the fourth quarter. Invesco Ltd. now owns 613,015 shares of the company's stock worth $5,959,000 after buying an additional 458,714 shares during the period. XTX Topco Ltd acquired a new stake in shares of Replimune Group during the fourth quarter worth $322,000. Virtus Investment Advisers LLC lifted its stake in shares of Replimune Group by 127.0% during the fourth quarter. Virtus Investment Advisers LLC now owns 26,133 shares of the company's stock worth $254,000 after buying an additional 14,622 shares during the period. SummitTX Capital L.P. acquired a new position in Replimune Group during the fourth quarter valued at $1,058,000. Finally, Susquehanna Portfolio Strategies LLC acquired a new position in Replimune Group during the fourth quarter valued at $650,000. 92.53% of the stock is currently owned by institutional investors and hedge funds.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company's proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune's lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.